SCHEMBL1337478

SCHEMBL1337478

CCCCOc1cccc(-c2ccc(NC(=O)c3ccccc3C(=O)O)c(F)c2)c1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 13/20 0.71
▸ NR4A2 P43354 5/20 0.71
▸ AKR1C2 P52895 1/20 0.53
▸ AKR1C1 Q04828 1/20 0.53
▸ NR1H4 Q96RI1 2/20 0.53
▸ RARA P10276 1/20 0.52
▸ RARB P10826 1/20 0.52
▸ NR4A1 P22736 2/20 0.51
▸ GAA P10253 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ JMJD7 P0C870 1/20 0.51
▸ NR4A3 Q92570 1/20 0.51
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PLK1 P53350 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336563 0.95 DHODH (0.64) DHODHNR4A2NR1H4NR4A1GAA
SCHEMBL1337458 0.91 DHODH (0.67) DHODHNR4A2NR1H4NR4A1GAA
SCHEMBL1335438 0.89 DHODH (0.66) DHODHNR4A2AKR1C2AKR1C1NR1H4
SCHEMBL1335695 0.85 NR1H4 (0.62) DHODHNR4A2AKR1C2AKR1C1NR1H4
SCHEMBL1336884 0.85 DHODH (0.78) DHODHNR4A2NR1H4NR4A1JMJD7
SCHEMBL29709148 0.84 DHODH (0.58) DHODHNR4A2AKR1C2AKR1C1NR1H4
SCHEMBL12129672 0.84 DHODH (0.58) DHODHNR4A2AKR1C2AKR1C1NR1H4
SCHEMBL1337784 0.84 NR1H4 (0.55) DHODHNR4A2AKR1C2AKR1C1NR1H4
SCHEMBL1337021 0.83 DHODH (0.67) DHODHNR4A2GAAL3MBTL1SMN1; SMN2
SCHEMBL1337732 0.82 NR1H4 (0.56) DHODHNR4A2NR1H4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 — — EP claimed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 — — US claimed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 — — US claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 — — US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 — — EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 — — US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 — — US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 — — US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885NR4A2 1697/4885AKR1C2 160/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885NR4A2 1697/4885AKR1C2 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback